Drug news

NICE recommends Eliquis (Pfizer/BMS) for Stroke Prevention

Read time: 1 mins

Last updated:24th Jan 2013

Published:24th Jan 2013

Source: Pharmawand

NICE (The National Institute of Health and Clinical Excellence) has recommended the oral anticoagulant Eliquis (apixaban) from BMS and Pfizer, as an option for Prevention of Sroke and Systemic Embolism in people with non-valvular Atrial Fibrillation with one or more risk factors.

The NICE appraisal committee considered that Eliquis was cost effective and more clinically effective for reducing stroke and systemic embolism and resulted in fewer bleeds than warfarin, the established standard of care.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves Alecensa (alectinib) as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Roche announced that the FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours greater than 4 cm or node positive), as detected by an FDA-approved test

2 mins

Drug news

Iomab-B (apamistamab) to overcome high-risk TP53 mutation resulting in significant improvement in overall survival in patients with active relapsed refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. announced that results from the Phase III SIERRA trial of Iomab-B (apamistamab) were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17

1 min

Drug news

FDA has granted a rolling New Drug Application (NDA) submission for suzetrigine (VX 548) in moderate-to-severe acute pain

Vertex Pharmaceuticals Incorporated announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548)

1 min

See all news